Key points from article :
A Scandinavian biotech company, Tribune Therapeutics, has secured €37 million in seed and Series A funding to develop a new class of treatments for fibrotic diseases—conditions marked by tissue scarring that can lead to organ failure. These diseases affect millions of people worldwide and include serious conditions such as idiopathic pulmonary fibrosis (IPF), a fatal lung disease with few effective treatment options.
The Oslo- and Stockholm-based company is pioneering a different strategy than most current fibrosis treatments, which typically focus on reducing inflammation. Instead, Tribune is targeting the CCN family of proteins that play a central role in scar formation. Its lead therapy, TRX-44, is a synthetic version of a natural protein called CCN5, which helps balance out the scarring process. By restoring this balance, TRX-44 aims to stop or even reverse fibrosis across multiple organs, including the lungs, liver, and kidneys.
The newly raised funds will be used to advance TRX-44 into clinical trials and expand Tribune’s pipeline of CCN-targeting drugs. Investors backing the company include major players like LifeArc Ventures, Novo Holdings, and HealthCap, reflecting strong confidence in Tribune’s novel approach. If successful, this could mark a significant breakthrough in managing and potentially curing life-threatening fibrotic diseases.
